Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MGCD0103: Additional Phase I/II data

Additional data from 52 evaluable patients in a Phase I/II trial (Trial 005) showed that MGCD0103 plus Vidaza azacitidine

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE